Shivanand
Shivanand Dhanure, Bangalore IN
Patent application number | Description | Published |
---|---|---|
20110159092 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING LINEZOLID AND PROCESS FOR PREPARING THE SAME - The present invention provides an extended release pharmaceutical composition suitable for once daily dosing comprising Linezolid or pharmaceutically acceptable salt, derivative, prodrug, metabolite and polymorph thereof and one or more pharmaceutically acceptable excipients and a process of preparing the same. The present invention further provides a method of treating bacterial infections in a mammal comprising administering an extended release, pharmaceutical composition suitable for once daily dosing comprising Linezolid capable of maintaining T>MIC for at least 24 hours. The present invention further provides an extended release pharmaceutical composition suitable for once daily dosing comprising Linezolid so that upon oral administration the maximum concentrations (C | 06-30-2011 |
Shivanand Hartimath, Karnataka IN
Patent application number | Description | Published |
---|---|---|
20090188309 | PROCEDURE FOR DIAGNOSING AN EXHAUST GAS TREATMENT DEVICE AND DEVICE FOR IMPLEMENTING THE PROCEDURE - Procedures for diagnosing an exhaust gas treatment device, which is dosing a reagent into the exhaust gas area of a combustion process, whereby the reagent is brought up to a dosing pressure and subsequently dosed, at which the diagnosis is undertaken with the aid of an evaluation of a pressure drop of the reagent, and a device for implementing the procedure are suggested. After turning off the pump a pressure drop that occurs afterwards is evaluated. The evaluation of the pressure drop considers a leakage loss of the pump. | 07-30-2009 |
Shivanand Majagi, Rogers, AK US
Patent application number | Description | Published |
---|---|---|
20130130154 | Fuel Cell Interconnect Heat Treatment Method - Methods for fabricating an interconnect for a fuel cell stack include placing a compressed metal powder interconnect on a porous support, and sintering the interconnect in the presence of a non-oxidizing gas. The method may further include placing the sintered interconnect on a porous support, and oxidizing the interconnect in the presence of flowing air, or placing the sintered interconnect on a dense, non-porous support, and oxidizing the interconnect in the presence of a gas comprising pure oxygen or an oxygen/inert gas mixture that is substantially nitrogen-free. | 05-23-2013 |
Shivanand Puthli, Mumbai IN
Patent application number | Description | Published |
---|---|---|
20090110717 | TRANSMUCOSAL COMPOSITION - The invention provides a composition for delivering active agents through transmucosal administration, more particularly through the buccal mucosa. The composition is a unique transmucosal disk ( | 04-30-2009 |
20090317464 | METHODS AND COMPOSITIONS FOR PRODUCING ANTI-ANDROGENIC EFFECTS - The invention provides a method and a composition for producing an anti-androgenic effect in a mammal. The method comprises administering a modified release pharmaceutical composition of bicalutamide to a mammal, with a reduced dosing frequency, for improved patient convenience and compliance. The composition of the invention also provides for a higher bioavailability and improved pharmacokinetic profile as compared to a conventional bicalutamide composition. | 12-24-2009 |
20100015224 | PROGRAMMABLE BUOYANT DELIVERY TECHNOLOGY - The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the System can be retained in the gastric region for a prolonged period of time. It comprises of a core (I), one or more layers (II, IV, V) coated over the core and a preformed hollow space (III). The invention also concerns with a process for preparation of the System and a method for treating/preventing diseases, by administering to a subject in need thereof, the System of the invention. | 01-21-2010 |
20100086592 | MODIFIED DOSAGE FORMS OF TACROLIMUS - The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during which substantially no amount of tacrolimus is released from the dosage form, after which a second amount of tacrolimus is released wherein said second amount is released from the delayed release dosage unit either immediately e.g. within 0-2 hours or over a period of time ranging from about 2-12 hours from its initial release from the delayed release dosage unit. The dosage form may further comprise additional amount of tacrolimus to provide additional pulse of tacrolimus. The dosage forms of tacrolimus exhibit improved bioavailability and reduced flux or fluctuation over existing composition of tacrolimus. A method of preparing the dosage forms is also described. | 04-08-2010 |
Shivanand Puthli, Maharashtra IN
Patent application number | Description | Published |
---|---|---|
20110160274 | FENOFIBRATE FORMULATION WITH ENHANCED ORAL BIOAVAILABILITY - The present invention provides a formulation of fenofibrate with enhanced oral bioavailability, simplicity of design and manufacture and absence of food effect. The formulation comprises fenofibrate dissolved in a lipophilic surfactant, with a hydrophilic surfactant optionally added. The formulation can be effectively used in the management and treatment of conditions such as hypertriglyceridemia, hypercholesterolemia and mixed dyslipidemia, and can also be effective at lower doses as compared to commercially available products. The invention additionally relates to the process of manufacture of the formulation and to dosage forms comprising the same. | 06-30-2011 |
Shivanand Puthli, New Delhi IN
Patent application number | Description | Published |
---|---|---|
20130280324 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PREGABALIN - The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations. | 10-24-2013 |
Shivanand Shivalli, Colorado Springs, CO US
Patent application number | Description | Published |
---|---|---|
20090025436 | LOCK ASSEMBLY - A lock cylinder for a door including an opening, and operable to interact with a latch bolt assembly. The lock cylinder includes a housing that has a cavity, and a plug assembly that has a casing and a plug housed in the casing and rotatable between a locked position and an unlocked position. The plug is operable to interact with the latch bolt assembly, and the casing is disposed within the cavity. The lock cylinder also includes a spin ring member that at least partially encloses the housing, and an adapter that is configured to be installed in the opening of the door and that includes a spin ring interface engaged with the spin ring member. The adapter further includes a shield portion extendable into the opening of the door, and the spin ring interface and the shield portion are formed as a single piece. | 01-29-2009 |